RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical Trial

VANCOUVER, British Columbia & SAN RAFAEL, Calif.–(BUSINESS WIRE)–MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and RepliCel Life Sciences, Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel”), a regenerative medicine company, today announced that RepliCel has joined MedCision’s ThawSTAR® Early Adopter Program, a novel program that helps companies and investigators de-risk thawing of cell therapies in early stage clinical trials through to commercialization and point-of-care. Each participant will receive a ThawSTAR® System on loan that is custom engineered for their unique cell therapy product.

Click here to view the full press release